A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Bristol-Myers Squibb
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

• Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive).

• Fasting glucose (FG) < - 240 mg/dL, while on metformin or antidiabetic diet alone.

• HbA1c (Hemoglobin A1c) in the range of 6.0-10.0%

Exclusion Criteria:

• Women of childbearing potential